Akari Therapeutics, Plc AKTX

AKTX Company Overview

Akari Therapeutics, Plc is a clinical-stage biotechnology company focused on developing therapies for rare and autoimmune diseases with significant unmet medical need. The company has historically concentrated on treatments targeting inflammatory and immune-mediated pathways, particularly through complement system modulation and related biologic approaches. Akari has operated within the biotechnology and biopharmaceutical industries, with research activities centered on orphan diseases, hematologic disorders, and inflammatory conditions.

The company’s principal value drivers have included its proprietary therapeutic candidates, intellectual property portfolio, and clinical development programs. Akari became known for advancing nomacopan, a recombinant inhibitor designed to target complement component C5 and leukotriene B4–mediated inflammation. Over time, the company evolved through restructuring initiatives, financing activities, and strategic transactions intended to broaden its pipeline and preserve operational flexibility. Public disclosures in SEC filings and investor materials indicate that Akari has pursued strategic alternatives and collaborations as part of its effort to transition from a single-asset-focused organization toward a broader development platform.